Mkt Cap$2.23T-1.74%
24h Vol$74.28B
BTC Dom56.3%
ETH Dom9.0%
F&G17Extreme Fear
BTC$62,686.00-1.67% ETH$1,666.62-3.16% USDT$0.9987-0.01% BNB$577.36-1.84% USDC$0.9996-0.01% XRP$1.10-1.88% SOL$69.40-3.23% TRX$0.329-1.01% FIGR_HELOC$1.03-0.16% HYPE$61.30-7.24% DOGE$0.0789-3.56% USDS$0.9997+0.00% RAIN$0.0157-2.06% LEO$9.49-0.84% ZEC$413.84-6.89% XLM$0.1911-3.05% BTC$62,686.00-1.67% ETH$1,666.62-3.16% USDT$0.9987-0.01% BNB$577.36-1.84% USDC$0.9996-0.01% XRP$1.10-1.88% SOL$69.40-3.23% TRX$0.329-1.01% FIGR_HELOC$1.03-0.16% HYPE$61.30-7.24% DOGE$0.0789-3.56% USDS$0.9997+0.00% RAIN$0.0157-2.06% LEO$9.49-0.84% ZEC$413.84-6.89% XLM$0.1911-3.05%
News

VERV

Total Stories
1
Section
VERV
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Market Analysis

Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?

Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.

Tim FriesJun 17, 20253 min read